Kanya Rajangam

Kanya Rajangam currently works at Turnstone Biologics, Inc., as Independent Director from 2011 and Senti Biosciences, Inc., as President, Chief Medical Officer, Head-R&D from 2024.
Dr. Rajangam also formerly worked at Nektar Therapeutics, as Executive Director in 2015, Onyx Pharmaceuticals, Inc., as Senior Medical Director from 2011 to 2015, Exelixis, Inc., as Associate Medical Director from 2008 to 2011, Turnstone Biologics Corp., as Independent Director from 2021 to 2025, Cleave Therapeutics, Inc., as Chief Medical Officer from 2016 to 2017, Atara Biotherapeutics, Inc., as Chief Medical Officer & Senior Vice President from 2017 to 2018, and Nkarta, Inc., as Chief Medical Officer from 2019 to 2022.
Dr. Rajangam received her doctorate degree in 2006 from Northwestern University and doctorate degree in 1996 from St. John's Medical College.